Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.06
NYSE:COO's Cash-to-Debt is ranked lower than
98% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. NYSE:COO: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:COO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.04 Max: 1.92
Current: 0.06
0
1.92
Equity-to-Asset 0.61
NYSE:COO's Equity-to-Asset is ranked higher than
57% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NYSE:COO: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:COO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.59 Max: 0.8
Current: 0.61
0.29
0.8
Interest Coverage 12.67
NYSE:COO's Interest Coverage is ranked lower than
67% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.88 vs. NYSE:COO: 12.67 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:COO' s Interest Coverage Range Over the Past 10 Years
Min: 1.07  Med: 12.72 Max: 38.48
Current: 12.67
1.07
38.48
Piotroski F-Score: 7
Altman Z-Score: 4.60
Beneish M-Score: -2.64
WACC vs ROIC
6.48%
8.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.72
NYSE:COO's Operating Margin % is ranked higher than
81% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. NYSE:COO: 17.72 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:COO' s Operating Margin % Range Over the Past 10 Years
Min: 4.82  Med: 16.44 Max: 19.61
Current: 17.72
4.82
19.61
Net Margin % 14.80
NYSE:COO's Net Margin % is ranked higher than
84% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. NYSE:COO: 14.80 )
Ranked among companies with meaningful Net Margin % only.
NYSE:COO' s Net Margin % Range Over the Past 10 Years
Min: -1.18  Med: 12.26 Max: 18.65
Current: 14.8
-1.18
18.65
ROE % 10.98
NYSE:COO's ROE % is ranked higher than
67% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.98 vs. NYSE:COO: 10.98 )
Ranked among companies with meaningful ROE % only.
NYSE:COO' s ROE % Range Over the Past 10 Years
Min: -0.79  Med: 8.75 Max: 12.88
Current: 10.98
-0.79
12.88
ROA % 6.56
NYSE:COO's ROA % is ranked higher than
73% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. NYSE:COO: 6.56 )
Ranked among companies with meaningful ROA % only.
NYSE:COO' s ROA % Range Over the Past 10 Years
Min: -0.45  Med: 5.35 Max: 9.74
Current: 6.56
-0.45
9.74
ROC (Joel Greenblatt) % 24.20
NYSE:COO's ROC (Joel Greenblatt) % is ranked higher than
70% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. NYSE:COO: 24.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:COO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.39  Med: 19.99 Max: 29.5
Current: 24.2
5.39
29.5
3-Year Revenue Growth Rate 7.90
NYSE:COO's 3-Year Revenue Growth Rate is ranked higher than
65% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. NYSE:COO: 7.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:COO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.4  Med: 9.6 Max: 26.4
Current: 7.9
5.4
26.4
3-Year EBITDA Growth Rate 5.70
NYSE:COO's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. NYSE:COO: 5.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:COO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 15.5 Max: 62.2
Current: 5.7
-8.6
62.2
3-Year EPS without NRI Growth Rate -2.10
NYSE:COO's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NYSE:COO: -2.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:COO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -15.2  Med: 14.9 Max: 36.4
Current: -2.1
-15.2
36.4
GuruFocus has detected 7 Warning Signs with The Cooper Companies Inc $NYSE:COO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:COO's 10-Y Financials

Financials (Next Earnings Date: 2017-06-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

COO Guru Trades in Q1 2016

Manning & Napier Advisors, Inc 600,385 sh (New)
Paul Tudor Jones 1,662 sh (New)
Steven Cohen 46,500 sh (New)
Ron Baron 270,063 sh (+11.02%)
David Carlson 210,000 sh (unchged)
Mario Gabelli 28,500 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 205,000 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Ken Fisher 93,114 sh (-0.79%)
» More
Q2 2016

COO Guru Trades in Q2 2016

Steven Cohen 268,400 sh (+477.20%)
Paul Tudor Jones 3,355 sh (+101.87%)
Ken Fisher 106,914 sh (+14.82%)
Ron Baron 270,131 sh (+0.03%)
David Carlson 210,000 sh (unchged)
Mario Gabelli 28,500 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 205,000 sh (unchged)
Manning & Napier Advisors, Inc 562,995 sh (-6.23%)
» More
Q3 2016

COO Guru Trades in Q3 2016

Pioneer Investments 188,076 sh (New)
Joel Greenblatt 14,334 sh (New)
Paul Tudor Jones 4,816 sh (+43.55%)
Ken Fisher 114,974 sh (+7.54%)
Steven Cohen 270,800 sh (+0.89%)
Mario Gabelli 28,500 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 205,000 sh (unchged)
Ron Baron 264,731 sh (-2.00%)
David Carlson 190,000 sh (-9.52%)
Manning & Napier Advisors, Inc 354,911 sh (-36.96%)
» More
Q4 2016

COO Guru Trades in Q4 2016

Jim Simons 213,098 sh (New)
Joel Greenblatt 133,681 sh (+832.61%)
Pioneer Investments 325,499 sh (+73.07%)
Ken Fisher 115,353 sh (+0.33%)
David Carlson 190,000 sh (unchged)
Ron Baron 264,731 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 350,771 sh (-1.17%)
Mario Gabelli 27,500 sh (-3.51%)
Eaton Vance Worldwide Health Sciences Fund 152,300 sh (-25.71%)
» More
» Details

Insider Trades

Latest Guru Trades with COO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339115    SIC: 3841
Compare:NYSE:RMD, NAS:HOLX, OTCPK:SAUHY, OTCPK:TRUMF, NYSE:WAT, NYSE:MTD, OTCPK:OCPNY, NYSE:WST, NYSE:STE, NAS:XRAY, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI, OTCPK:CLPBY, OTCPK:ANSLY, NAS:PODD, NYSE:HAE, OTCPK:TOPCF, NYSE:HYH » details
Traded in other countries:CP6.Germany, COO.Mexico,
The Cooper Companies Inc is a medical device company. Through its subsidiaries, it manufactures products for contact lens wearers and supplies women's health clinicians with products and treatment options to improve the delivery of healthcare to women.

Cooper Companies operates two units: Cooper Vision and Cooper Surgical. Accounting for over 80% of total sales, Cooper Vision is one of the world's top four developers and manufacturers of contact lenses. Over 50% of Cooper Vision's sales are international. At roughly 20% of total sales, Cooper Surgical develops and manufactures diagnostic and surgical products for gynecologists and obstetricians.

Guru Investment Theses on The Cooper Companies Inc

Baron Funds Comments on The Cooper Companies - Jan 26, 2016

Shares of The Cooper Companies, Inc. (NYSE:COO), a global contact lens manufacturer, fell after its earnings fell short of Wall Street expectations. Results were negatively impacted by missteps in integrating its recent acquisition of Sauflon Pharmaceuticals Ltd., a British contact lens company, as well as fallout from new competitive lenses. Management projected moderating market share gains and lowered the company’s targeted five-year growth rate. Although disappointed, we remain cautiously optimistic, given Cooper’s reduced valuation and our belief that its revised earnings targets are achievable. Furthermore, we believe that shifts in the contact lens market toward greater adoption of silicon hydrogel lenses and daily modalities will play to Cooper’s strengths.



From Baron Funds' Baron Asset Fund commentary for fourth quarter 2015.



Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 32.79
COO's PE Ratio is ranked lower than
57% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.61 vs. COO: 32.79 )
Ranked among companies with meaningful PE Ratio only.
COO' s PE Ratio Range Over the Past 10 Years
Min: 8.06  Med: 22.64 Max: 1011.75
Current: 32.79
8.06
1011.75
Forward PE Ratio 21.83
COO's Forward PE Ratio is ranked higher than
67% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.75 vs. COO: 21.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.79
COO's PE Ratio without NRI is ranked lower than
56% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.85 vs. COO: 32.79 )
Ranked among companies with meaningful PE Ratio without NRI only.
COO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.06  Med: 22.64 Max: 1011.75
Current: 32.79
8.06
1011.75
Price-to-Owner-Earnings 29.25
COO's Price-to-Owner-Earnings is ranked higher than
52% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. COO: 29.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
COO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.85  Med: 24.14 Max: 195
Current: 29.25
13.85
195
PB Ratio 3.45
COO's PB Ratio is ranked lower than
51% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. COO: 3.45 )
Ranked among companies with meaningful PB Ratio only.
COO' s PB Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.86 Max: 3.62
Current: 3.45
0.37
3.62
PS Ratio 4.85
COO's PS Ratio is ranked lower than
68% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. COO: 4.85 )
Ranked among companies with meaningful PS Ratio only.
COO' s PS Ratio Range Over the Past 10 Years
Min: 0.51  Med: 2.86 Max: 5.22
Current: 4.85
0.51
5.22
Price-to-Free-Cash-Flow 24.90
COO's Price-to-Free-Cash-Flow is ranked higher than
58% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.12 vs. COO: 24.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
COO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.33  Med: 24.86 Max: 353.03
Current: 24.9
7.33
353.03
Price-to-Operating-Cash-Flow 18.48
COO's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.55 vs. COO: 18.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
COO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.63  Med: 14.81 Max: 21.94
Current: 18.48
5.63
21.94
EV-to-EBIT 31.35
COO's EV-to-EBIT is ranked lower than
78% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.23 vs. COO: 31.35 )
Ranked among companies with meaningful EV-to-EBIT only.
COO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 21.3 Max: 72
Current: 31.35
11.4
72
EV-to-EBITDA 20.29
COO's EV-to-EBITDA is ranked lower than
61% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.75 vs. COO: 20.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
COO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.9  Med: 15 Max: 24.4
Current: 20.29
6.9
24.4
PEG Ratio 4.05
COO's PEG Ratio is ranked lower than
67% of the 55 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.82 vs. COO: 4.05 )
Ranked among companies with meaningful PEG Ratio only.
COO' s PEG Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.23 Max: 22.9
Current: 4.05
0.78
22.9
Shiller PE Ratio 50.89
COO's Shiller PE Ratio is ranked lower than
59% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.77 vs. COO: 50.89 )
Ranked among companies with meaningful Shiller PE Ratio only.
COO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.2  Med: 36.82 Max: 59.69
Current: 50.89
7.2
59.69
Current Ratio 1.71
COO's Current Ratio is ranked lower than
71% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. COO: 1.71 )
Ranked among companies with meaningful Current Ratio only.
COO' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 2.18 Max: 3.46
Current: 1.71
1.1
3.46
Quick Ratio 0.89
COO's Quick Ratio is ranked lower than
80% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. COO: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
COO' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.23 Max: 2.95
Current: 0.89
0.69
2.95
Days Inventory 196.49
COO's Days Inventory is ranked lower than
77% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. COO: 196.49 )
Ranked among companies with meaningful Days Inventory only.
COO' s Days Inventory Range Over the Past 10 Years
Min: 167.05  Med: 203.22 Max: 230.08
Current: 196.49
167.05
230.08
Days Sales Outstanding 52.66
COO's Days Sales Outstanding is ranked higher than
70% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.07 vs. COO: 52.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
COO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.66  Med: 58.23 Max: 63.16
Current: 52.66
52.66
63.16
Days Payable 46.18
COO's Days Payable is ranked lower than
53% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.88 vs. COO: 46.18 )
Ranked among companies with meaningful Days Payable only.
COO' s Days Payable Range Over the Past 10 Years
Min: 27.82  Med: 52.54 Max: 70.39
Current: 46.18
27.82
70.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.03
COO's Dividend Yield % is ranked lower than
100% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.25 vs. COO: 0.03 )
Ranked among companies with meaningful Dividend Yield % only.
COO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.03  Med: 0.08 Max: 0.52
Current: 0.03
0.03
0.52
Dividend Payout Ratio 0.01
COO's Dividend Payout Ratio is ranked higher than
98% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. COO: 0.01 )
Ranked among companies with meaningful Dividend Payout Ratio only.
COO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.01 Max: 0.04
Current: 0.01
0.01
0.04
Forward Dividend Yield % 0.03
COO's Forward Dividend Yield % is ranked lower than
100% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. COO: 0.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.03
COO's 5-Year Yield-on-Cost % is ranked lower than
99% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. COO: 0.03 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
COO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.03  Med: 0.08 Max: 0.52
Current: 0.03
0.03
0.52
3-Year Average Share Buyback Ratio -0.50
COO's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. COO: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
COO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.9  Med: -1 Max: 1.2
Current: -0.5
-12.9
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 237.54
COO's Price-to-Tangible-Book is ranked lower than
100% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.31 vs. COO: 237.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
COO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.27  Med: 9.27 Max: 1768
Current: 237.54
3.27
1768
Price-to-Intrinsic-Value-Projected-FCF 1.93
COO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. COO: 1.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
COO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.66 Max: 5.86
Current: 1.93
0.57
5.86
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.06
COO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
68% of the 28 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.07 vs. COO: 3.06 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.69
COO's Price-to-Median-PS-Value is ranked lower than
80% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. COO: 1.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
COO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1.04 Max: 2.58
Current: 1.69
0.26
2.58
Price-to-Peter-Lynch-Fair-Value 5.71
COO's Price-to-Peter-Lynch-Fair-Value is ranked lower than
89% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.32 vs. COO: 5.71 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
COO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.38 Max: 70
Current: 5.71
0.6
70
Price-to-Graham-Number 18.60
COO's Price-to-Graham-Number is ranked lower than
100% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.58 vs. COO: 18.60 )
Ranked among companies with meaningful Price-to-Graham-Number only.
COO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.78  Med: 2.69 Max: 54.57
Current: 18.6
0.78
54.57
Earnings Yield (Greenblatt) % 3.19
COO's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. COO: 3.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
COO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 4.7 Max: 8.8
Current: 3.19
1.4
8.8
Forward Rate of Return (Yacktman) % 8.18
COO's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.56 vs. COO: 8.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
COO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 14.15 Max: 23.1
Current: 8.18
-2
23.1

More Statistics

Revenue (TTM) (Mil) $2,016
EPS (TTM) $ 6.07
Beta0.63
Short Percentage of Float3.09%
52-Week Range $147.77 - 202.70
Shares Outstanding (Mil)48.94

Analyst Estimate

Oct17 Oct18
Revenue (Mil $) 2,111 2,250
EPS ($) 9.19 10.34
EPS without NRI ($) 9.19 10.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.88%
Dividends per Share ($) 0.06 0.07
» More Articles for COO

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlights Jul 06 2016 
Weekly CFO Sells Highlight Jun 13 2016 
Baron Funds Comments on The Cooper Companies Jan 26 2016 
Steve Mandel Buys Visa, DaVita Healthcare In Q4 Feb 19 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Weekly CEO Sells Highlight: Cooper Companies, Broadcom Corp, Realpage Inc, and Freescale Semiconduct Jul 14 2014 
Baron Funds Comments on The Cooper Companies May 02 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Manning & Napier New Buys of Q1 Apr 19 2013 
The Cooper Companies: Not Eyeing It Yet Nov 27 2012 

More From Other Websites
The Cooper Companies Hits 52-Week High on Multiple Positives Mar 24 2017
Cooper Companies (COO) Increase Share Repurchase Program Mar 22 2017
The Cooper Cos., Inc. :COO-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017 Mar 22 2017
The Cooper Companies Announces Expanded Share Repurchase Program Mar 21 2017
The Cooper Cos., Inc. : COO-US: Dividend Analysis : January 23rd, 2017 (record date) : By the... Mar 17 2017
Post Earnings Coverage as Cooper's Quarterly Revenue Grew 11%; EPS Surged 46% Mar 17 2017
COOPER COMPANIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 16 2017
COOPER COMPANIES INC Financials Mar 09 2017
Cooper Companies (COO) Receives ISO 15189 Accreditation Mar 09 2017
CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive... Mar 08 2017
CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive... Mar 08 2017
COOPER COMPANIES INC Files SEC form 10-Q, Quarterly Report Mar 03 2017
The Cooper Companies (COO) Beats Earnings Estimates in Q1 Mar 03 2017
[$$] Cooper Revises Guidance as Profit Beats Projections Mar 02 2017
COOPER COMPANIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 02 2017
The Cooper Companies Announces First Quarter Results Mar 02 2017
Q1 2017 Cooper Companies Inc Earnings Release - 4:15 pm ET Mar 02 2017
Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store? Feb 27 2017
Post Earnings Coverage as Becton, Dickinson and Co.'s Revenue Grew 6.1%; Adjusted EPS Gained 19.4%... Feb 16 2017
The Cooper Companies Announces Release Date for First Quarter 2017 Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)